Survival outcomes after HSCT
| Group . | n . | 2-y EFS, % (95% CI) . | 2-y OS, % (95% CI) . |
|---|---|---|---|
| All patients | 47 | 49 (35-64) | 63 (49-78) |
| BCR-ABL1 mutation | |||
| Yes | 19 | 36 (14-58) | 44 (20-67) |
| No | 28 | 58 (39-77) | 76 (59-93) |
| P | .05 | .02 | |
| Stage | |||
| CP | 16 | 62 (39-86) | 72 (49-96) |
| AP | 31 | 44 (25-61) | 59 (41-77) |
| P | .27 | .30 | |
| CP only | |||
| BCR-ABL1 mutation | 4 | 25 (0-67) | 33 (0-87) |
| No BCR-ABL1 mutation | 12 | 75 (50-99) | 81 (58-100) |
| P | .20 | .13 | |
| Advanced phase only | |||
| BCR-ABL1 mutation | 15 | 40 (15-65) | 46 (20-71) |
| No BCR-ABL1 mutation | 16 | 45 (18-72) | 72 (48-96) |
| P | .20 | .12 |
| Group . | n . | 2-y EFS, % (95% CI) . | 2-y OS, % (95% CI) . |
|---|---|---|---|
| All patients | 47 | 49 (35-64) | 63 (49-78) |
| BCR-ABL1 mutation | |||
| Yes | 19 | 36 (14-58) | 44 (20-67) |
| No | 28 | 58 (39-77) | 76 (59-93) |
| P | .05 | .02 | |
| Stage | |||
| CP | 16 | 62 (39-86) | 72 (49-96) |
| AP | 31 | 44 (25-61) | 59 (41-77) |
| P | .27 | .30 | |
| CP only | |||
| BCR-ABL1 mutation | 4 | 25 (0-67) | 33 (0-87) |
| No BCR-ABL1 mutation | 12 | 75 (50-99) | 81 (58-100) |
| P | .20 | .13 | |
| Advanced phase only | |||
| BCR-ABL1 mutation | 15 | 40 (15-65) | 46 (20-71) |
| No BCR-ABL1 mutation | 16 | 45 (18-72) | 72 (48-96) |
| P | .20 | .12 |
CI indicates confidence interval.